According to a new study, which will be presented at the American Society of Clinical Oncology’s annual meeting on the week of May 25, GLP-1 drugs may be linked to lowering the risk of cancer progression.
Mark Orland, an internal medicine physician at Cleveland Clinic, and his team studied over 10,000 people who had been diagnosed with one of seven types of cancer, such as breast, colorectal, kidney, liver, lung, pancreatic, and prostate cancers, with the patients being in different stages of the disease.
The findings show that the patients who were given GLP-1 medications were less likely to have their tumors metastasize or spread for all seven types of cancer, except for kidney cancer.
Indeed, there has been a growing body of research studying the effects of GLP-1 drugs that have been gaining more popularity lately. Some of the most well-known of them are Mounjaro and Ozempic.
Mounjaro and Ozempic are two of the most popular injectable medications to help control blood sugar levels in people with type 2 diabetes. Both drugs can also lead to significant weight loss. But while Mounjaro and Ozempic share similar benefits, there are key differences in how they work, with each having certain advantages over the other. How you choose which medication to go with depends on a number of factors, including patient response, tolerance levels, cost, and other health conditions. So, how can you make an informed choice that's right for you?
If you're thinking about using Mounjaro or Ozempic, click on and learn about the differences between the two drugs, and find out how each one works.